OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
PD-1 and its ligands are important immune checkpoints in cancer
Yinan Dong, Qian Sun, Xinwei Zhang
Oncotarget (2016) Vol. 8, Iss. 2, pp. 2171-2186
Open Access | Times Cited: 295
Yinan Dong, Qian Sun, Xinwei Zhang
Oncotarget (2016) Vol. 8, Iss. 2, pp. 2171-2186
Open Access | Times Cited: 295
Showing 1-25 of 295 citing articles:
Top 10 Challenges in Cancer Immunotherapy
Priti S. Hegde, Daniel S. Chen
Immunity (2020) Vol. 52, Iss. 1, pp. 17-35
Open Access | Times Cited: 1604
Priti S. Hegde, Daniel S. Chen
Immunity (2020) Vol. 52, Iss. 1, pp. 17-35
Open Access | Times Cited: 1604
Colorectal Cancer Immunotherapy: Options and Strategies
Nor Adzimah Johdi, Nur Fazilah Sukor
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 346
Nor Adzimah Johdi, Nur Fazilah Sukor
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 346
Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma
Michael B. Atkins, Nizar M. Tannir
Cancer Treatment Reviews (2018) Vol. 70, pp. 127-137
Open Access | Times Cited: 336
Michael B. Atkins, Nizar M. Tannir
Cancer Treatment Reviews (2018) Vol. 70, pp. 127-137
Open Access | Times Cited: 336
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dongrui Wang, Xianlin Wu, Yingli Sun
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 287
Dongrui Wang, Xianlin Wu, Yingli Sun
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 287
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer
Xinxin Zhu, Jinghe Lang
Oncotarget (2017) Vol. 8, Iss. 57, pp. 97671-97682
Open Access | Times Cited: 278
Xinxin Zhu, Jinghe Lang
Oncotarget (2017) Vol. 8, Iss. 57, pp. 97671-97682
Open Access | Times Cited: 278
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Luisa Barrueto, Francheska Caminero, Lindsay Cash, et al.
Translational Oncology (2020) Vol. 13, Iss. 3, pp. 100738-100738
Open Access | Times Cited: 234
Luisa Barrueto, Francheska Caminero, Lindsay Cash, et al.
Translational Oncology (2020) Vol. 13, Iss. 3, pp. 100738-100738
Open Access | Times Cited: 234
Role of tumor-infiltrating lymphocytes in patients with solid tumors: Can a drop dig a stone?
Giuseppe Badalamenti, Daniele Fanale, Lorena Incorvaia, et al.
Cellular Immunology (2018) Vol. 343, pp. 103753-103753
Closed Access | Times Cited: 200
Giuseppe Badalamenti, Daniele Fanale, Lorena Incorvaia, et al.
Cellular Immunology (2018) Vol. 343, pp. 103753-103753
Closed Access | Times Cited: 200
Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multi-omics analysis
Ann Taber, Emil Christensen, Philippe Lamy, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 176
Ann Taber, Emil Christensen, Philippe Lamy, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 176
Revisiting Immunotherapy: A Focus on Prostate Cancer
Ha-Ram Cha, Joo Hyoung Lee, Selvarangan Ponnazhagan
Cancer Research (2020) Vol. 80, Iss. 8, pp. 1615-1623
Open Access | Times Cited: 171
Ha-Ram Cha, Joo Hyoung Lee, Selvarangan Ponnazhagan
Cancer Research (2020) Vol. 80, Iss. 8, pp. 1615-1623
Open Access | Times Cited: 171
Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, et al.
Journal for ImmunoTherapy of Cancer (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 170
Asim Amin, Elizabeth R. Plimack, Marc S. Ernstoff, et al.
Journal for ImmunoTherapy of Cancer (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 170
Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy
Soumaya Kouidhi, Farhat Ben Ayed, Amel Benammar Elgaaïed
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 166
Soumaya Kouidhi, Farhat Ben Ayed, Amel Benammar Elgaaïed
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 166
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment
Bo Wu, Xiang Shi, Meixi Jiang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 95
Bo Wu, Xiang Shi, Meixi Jiang, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 95
Clear Cell Renal Cell Carcinoma: From Biology to Treatment
Adam M. Kase, Daniel J. George, Sundhar Ramalingam
Cancers (2023) Vol. 15, Iss. 3, pp. 665-665
Open Access | Times Cited: 49
Adam M. Kase, Daniel J. George, Sundhar Ramalingam
Cancers (2023) Vol. 15, Iss. 3, pp. 665-665
Open Access | Times Cited: 49
Uncovering the complex role of interferon-gamma in suppressing type 2 immunity to cancer
Asif Ahmad Bhat, Ahsas Goyal, Riya Thapa, et al.
Cytokine (2023) Vol. 171, pp. 156376-156376
Closed Access | Times Cited: 48
Asif Ahmad Bhat, Ahsas Goyal, Riya Thapa, et al.
Cytokine (2023) Vol. 171, pp. 156376-156376
Closed Access | Times Cited: 48
Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy
Deepak Chandra Joshi, Anurag Sharma, Sonima Prasad, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 22
Deepak Chandra Joshi, Anurag Sharma, Sonima Prasad, et al.
Discover Oncology (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 22
A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy
Masahiro Shibata, Kendall Ham, Mohammad Obaidul Hoque
International Journal of Cancer (2018) Vol. 143, Iss. 9, pp. 2133-2144
Open Access | Times Cited: 150
Masahiro Shibata, Kendall Ham, Mohammad Obaidul Hoque
International Journal of Cancer (2018) Vol. 143, Iss. 9, pp. 2133-2144
Open Access | Times Cited: 150
PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity
Doumet Georges Helou, Pedram Shafiei-Jahani, Richard Lo, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 137
Doumet Georges Helou, Pedram Shafiei-Jahani, Richard Lo, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 137
Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy
Muhammad Khan, Zhihong Zhao, Sumbal Arooj, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 128
Muhammad Khan, Zhihong Zhao, Sumbal Arooj, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 128
Oxaliplatin induces immunogenic cell death in hepatocellular carcinoma cells and synergizes with immune checkpoint blockade therapy
Hanzhang Zhu, Yuqiang Shan, Ke Ge, et al.
Cellular Oncology (2020) Vol. 43, Iss. 6, pp. 1203-1214
Closed Access | Times Cited: 122
Hanzhang Zhu, Yuqiang Shan, Ke Ge, et al.
Cellular Oncology (2020) Vol. 43, Iss. 6, pp. 1203-1214
Closed Access | Times Cited: 122
Liver Allograft Failure After Nivolumab Treatment—A Case Report With Systematic Literature Research
Dimitri Gassmann, Stefan Weiler, Joachim C. Mertens, et al.
Transplantation Direct (2018) Vol. 4, Iss. 8, pp. e376-e376
Open Access | Times Cited: 120
Dimitri Gassmann, Stefan Weiler, Joachim C. Mertens, et al.
Transplantation Direct (2018) Vol. 4, Iss. 8, pp. e376-e376
Open Access | Times Cited: 120
The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma
Boyang Chang, Tao Huang, Huajun Wei, et al.
Cancer Immunology Immunotherapy (2018) Vol. 68, Iss. 3, pp. 353-363
Open Access | Times Cited: 112
Boyang Chang, Tao Huang, Huajun Wei, et al.
Cancer Immunology Immunotherapy (2018) Vol. 68, Iss. 3, pp. 353-363
Open Access | Times Cited: 112
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials
Omid Kooshkaki, Afshin Derakhshani, Negar Hosseinkhani, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 12, pp. 4427-4427
Open Access | Times Cited: 101
Omid Kooshkaki, Afshin Derakhshani, Negar Hosseinkhani, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 12, pp. 4427-4427
Open Access | Times Cited: 101
The Prognostic and Therapeutic Value of PD-L1 in Glioma
Ruo Qiao Chen, Feng Liu, Xin Qiu, et al.
Frontiers in Pharmacology (2019) Vol. 9
Open Access | Times Cited: 100
Ruo Qiao Chen, Feng Liu, Xin Qiu, et al.
Frontiers in Pharmacology (2019) Vol. 9
Open Access | Times Cited: 100
Hyperprogression as a distinct outcome after immunotherapy
Jesús Fuentes‐Antrás, Mariano Provencio, Eduardo Díaz‐Rubio
Cancer Treatment Reviews (2018) Vol. 70, pp. 16-21
Closed Access | Times Cited: 96
Jesús Fuentes‐Antrás, Mariano Provencio, Eduardo Díaz‐Rubio
Cancer Treatment Reviews (2018) Vol. 70, pp. 16-21
Closed Access | Times Cited: 96
PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
Junyu Long, Jianzhen Lin, Anqiang Wang, et al.
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 95
Junyu Long, Jianzhen Lin, Anqiang Wang, et al.
Journal of Hematology & Oncology (2017) Vol. 10, Iss. 1
Open Access | Times Cited: 95
